| Literature DB >> 31591235 |
Catharina Hagerling1,2, Hugo Gonzalez3, Kiarash Salari3, Chih-Yang Wang3, Charlene Lin3, Isabella Robles3, Merel van Gogh3, Annika Dejmek4, Karin Jirström2, Zena Werb1,5.
Abstract
Metastatic behavior varies significantly among breast cancers. Mechanisms explaining why the majority of breast cancer patients never develop metastatic outgrowth are largely lacking but could underlie the development of novel immunotherapeutic target molecules. Here we show interplay between nonmetastatic primary breast cancer and innate immune response, acting together to control metastatic progression. The primary tumor systemically recruits IFNγ-producing immune effector monocytes to the lung. IFNγ up-regulates Tmem173/STING in neutrophils and enhances their killing capacity. The immune effector monocytes and tumoricidal neutrophils target disseminated tumor cells in the lungs, preventing metastatic outgrowth. Importantly, our findings could underlie the development of immunotherapeutic target molecules that augment the function of immune effector monocytes and neutrophils.Entities:
Keywords: CCL2; CCR2; STING; immune effector monocytes; metastatic breast cancer
Year: 2019 PMID: 31591235 PMCID: PMC6815161 DOI: 10.1073/pnas.1907660116
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205